Want to see CNTX full AI Analyst Report?
Total Valuation
Context Therapeutics has a market cap or net worth of $47.75M. The enterprise value is $9.98.
Market Cap$47.75M
Enterprise Value$9.98
Share Statistics
Context Therapeutics has 91,879,170 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding91,879,170
Owned by Insiders1.35%
Owned by Institutions41.75%
Financial Efficiency
Context Therapeutics’s return on equity (ROE) is -0.60 and return on invested capital (ROIC) is -65.53%.
Return on Equity (ROE)-0.60
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-65.53%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee0.00
Profits Per Employee-2.41M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Context Therapeutics is ―. Context Therapeutics’s PEG ratio is 0.22.
PE Ratio―
PS Ratio0.00
PB Ratio2.31
Price to Fair Value2.31
Price to FCF-5.30
Price to Operating Cash Flow-1.40
PEG Ratio0.22
Income Statement
In the last 12 months, Context Therapeutics had revenue of 0.00 and earned -36.12M in profits. Earnings per share was -0.38.
Revenue0.00
Gross Profit0.00
Operating Income-39.70M
Pretax Income-36.12M
Net Income-36.12M
EBITDA-36.11M
Earnings Per Share (EPS)-0.38
Cash Flow
In the last 12 months, operating cash flow was -33.97M and capital expenditures -55.75K, giving a free cash flow of -34.03M billion.
Operating Cash Flow-33.97M
Free Cash Flow-34.03M
Free Cash Flow per Share-0.37
Dividends & Yields
Context Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.58
52-Week Price Change-42.66%
50-Day Moving Average0.62
200-Day Moving Average1.67
Relative Strength Index (RSI)39.06
Average Volume (3m)3.94M
Important Dates
Context Therapeutics upcoming earnings date is Nov 11, 2026, After Close (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Context Therapeutics as a current ratio of 8.52, with Debt / Equity ratio of 0.64%
Current Ratio8.52
Quick Ratio8.52
Debt to Market Cap0.00
Net Debt to EBITDA1.82
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Context Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Context Therapeutics EV to EBITDA ratio is -2.05, with an EV/FCF ratio of -2.80.
EV to Sales0.00
EV to EBITDA-2.05
EV to Free Cash Flow-2.80
EV to Operating Cash Flow-2.81
Balance Sheet
Context Therapeutics has $42.99M in cash and marketable securities with $244.99K in debt, giving a net cash position of $42.75M billion.
Cash & Marketable Securities$42.99M
Total Debt$244.99K
Net Cash$42.75M
Net Cash Per Share$0.47
Tangible Book Value Per Share$0.64
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Context Therapeutics is $3.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$3.83
Price Target Upside528.42% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast-23.49%